These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 23360137)

  • 21. Commentary on "Alzheimer's disease drug development and the problem of the blood-brain barrier." The blood-brain barrier: a physical and conceptual challenge.
    Hachinski V; Lee TY
    Alzheimers Dement; 2009 Sep; 5(5):435-6. PubMed ID: 19751924
    [No Abstract]   [Full Text] [Related]  

  • 22. Neural network dysfunction in Alzheimer's disease: a drug development perspective.
    Small DH
    Drug News Perspect; 2007 Nov; 20(9):557-63. PubMed ID: 18176660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease.
    Feng Z; Chang Y; Cheng Y; Zhang BL; Qu ZW; Qin C; Zhang JT
    J Pineal Res; 2004 Sep; 37(2):129-36. PubMed ID: 15298672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Tong Luo Jiu Nao on Aβ-degrading enzymes in AD rat brains.
    Liu Y; Hua Q; Lei H; Li P
    J Ethnopharmacol; 2011 Sep; 137(2):1035-46. PubMed ID: 21798326
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Theoretical studies of Alzheimer's disease drug candidate 3-[(2,4-dimethoxy)benzylidene]-anabaseine (GTS-21) and its derivatives.
    Wei DQ; Sirois S; Du QS; Arias HR; Chou KC
    Biochem Biophys Res Commun; 2005 Dec; 338(2):1059-64. PubMed ID: 16256952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peptides and therapeutic proteins--SRI conference. New opportunities for macromolecule development, delivery and commercialization. 17-18 November 2005, Philadelphia, PA, USA.
    Craik D
    IDrugs; 2006 Jan; 9(1):25-7. PubMed ID: 16374728
    [No Abstract]   [Full Text] [Related]  

  • 27. Neuroinflammation in Alzheimer's disease: different molecular targets and potential therapeutic agents including curcumin.
    Ray B; Lahiri DK
    Curr Opin Pharmacol; 2009 Aug; 9(4):434-44. PubMed ID: 19656726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alzheimer's disease--from cause to cure?
    Vines G
    Trends Biotechnol; 1993 Feb; 11(2):49-55. PubMed ID: 7763478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-n oligomers as therapeutic targets of Alzheimer's disease.
    Ono K; Yamada M
    J Neurochem; 2011 Apr; 117(1):19-28. PubMed ID: 21244429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant human NGF-loaded microspheres promote survival of basal forebrain cholinergic neurons and improve memory impairments of spatial learning in the rat model of Alzheimer's disease with fimbria-fornix lesion.
    Gu H; Long D; Song C; Li X
    Neurosci Lett; 2009 Apr; 453(3):204-9. PubMed ID: 19429036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A small molecule targeting the multifactorial nature of Alzheimer's disease.
    Cavalli A; Bolognesi ML; Capsoni S; Andrisano V; Bartolini M; Margotti E; Cattaneo A; Recanatini M; Melchiorre C
    Angew Chem Int Ed Engl; 2007; 46(20):3689-92. PubMed ID: 17397121
    [No Abstract]   [Full Text] [Related]  

  • 32. Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer's disease.
    Yamada K; Uchida S; Takahashi S; Takayama M; Nagata Y; Suzuki N; Shirakura S; Kanda T
    Brain Res; 2010 Sep; 1352():176-86. PubMed ID: 20627092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A case for a non-transgenic animal model of Alzheimer's disease.
    Stéphan A; Phillips AG
    Genes Brain Behav; 2005 Apr; 4(3):157-72. PubMed ID: 15810904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alzheimer's disease and diabetes: an integrative view of the role of mitochondria, oxidative stress, and insulin.
    Moreira PI
    J Alzheimers Dis; 2012; 30 Suppl 2():S199-215. PubMed ID: 22269163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus.
    Hanyu H; Sato T; Kiuchi A; Sakurai H; Iwamoto T
    J Am Geriatr Soc; 2009 Jan; 57(1):177-9. PubMed ID: 19170800
    [No Abstract]   [Full Text] [Related]  

  • 36. [Drug therapy of Alzheimer's disease. Problems and strategy in development of new therapeutic drugs for Alzheimer's disease].
    Moroji T; Matsuzaki I
    Nihon Rinsho; 1988 Jul; 46(7):1586-91. PubMed ID: 2906096
    [No Abstract]   [Full Text] [Related]  

  • 37. Medicine's next level.
    Carmichael M
    Newsweek; 2004 Dec; 144(23):44-6, 49-50. PubMed ID: 15605719
    [No Abstract]   [Full Text] [Related]  

  • 38. Improved brain delivery of a nonsteroidal anti-inflammatory drug with a synthetic glyceride ester: a preliminary attempt at a CNS drug delivery system for the therapy of Alzheimer's disease.
    Deguchi Y; Hayashi H; Fujii S; Naito T; Yokoyama Y; Yamada S; Kimura R
    J Drug Target; 2000; 8(6):371-81. PubMed ID: 11328663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psychopharmacology of Alzheimer's disease.
    Procter AW
    Br J Hosp Med; 1996 Feb 21-Mar 5; 55(4):191-4. PubMed ID: 8777499
    [No Abstract]   [Full Text] [Related]  

  • 40. Approaches to rational drug development in Alzheimer's disease.
    Iversen LL; Iversen SD; Freedman SB; Dawson G; Rupniak N; Hargreaves RJ; Showell GA; Street LJ; Baker R
    Drug Des Discov; 1993; 9(3-4):251-9. PubMed ID: 8400006
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.